Domenico Mallardo, MD, on Anti-CTLA4 Agents in Melanoma
Domenico Mallardo, MD, Istituto Nazionale Tumori " Fondazione Pascale " in Naples, discusses results from his trial – designed to evaluate anti-CTLA4 agents in patients with melanoma who relapsed on treatment with ipilimumab (Yervoy), which was presented at the 34th Annual Meeting& Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019). (Source: CancerNetwork)
Source: CancerNetwork - November 14, 2019 Category: Cancer & Oncology Authors: Domenico Mallardo, MD Source Type: news
FDA Grants Priority Review to Opdivo-Yervoy Combo in Advanced HCC
The FDA has accepted the supplemental biologics license application and granted breakthrough therapy designation to nivolumab plus ipilimumab for the treatment of patients with advanced hepatocellular carcinoma previously treated with sorafenib. (Source: CancerNetwork)
Source: CancerNetwork - November 11, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news
Bristol-Myers' immunotherapies show promise in lung cancer trial; shares rise
Bristol-Myers Squibb Co said on Tuesday an interim analysis of a late-stage trial testing a combination of its immuno-oncology drugs Opdivo and Yervoy met the main goal of extending life of previously untreated lung cancer patients. (Source: Reuters: Health)
Source: Reuters: Health - October 22, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
Nivolumab Therapy Prolongs Survival in Advanced Melanoma
Overall survival at five years longer with nivolumab + ipilimumab, nivolumab alone versus ipilimumab (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 30, 2019 Category: Cancer & Oncology Tags: Dermatology, Oncology, Pharmacy, Conference News, Source Type: news
Nivolumab Therapy Prolongs Survival in Advanced Melanoma
MONDAY, Sept. 30, 2019 -- More patients with advanced melanoma receiving nivolumab plus ipilimumab or nivolumab alone have sustained long-term survival at five years compared with those receiving ipilimumab alone, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 30, 2019 Category: Pharmaceuticals Source Type: news
Could All Patients With Advanced NSCLC Go Chemo-Free? Could All Patients With Advanced NSCLC Go Chemo-Free?
Results from CheckMate 227 suggest that combination nivolumab and ipilimumab may eliminate the need for chemotherapy in advanced NSCLC, regardless of PD-L1 status.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 28, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
One in Two Patients With Metastatic Melanoma Alive After 5 Years One in Two Patients With Metastatic Melanoma Alive After 5 Years
With the combination of ipilimumab and nivolumab, 50% of patients are still alive after 5 years, a survival rate remarkably higher than that seen with either agent alone.Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - September 28, 2019 Category: Pathology Tags: Hematology-Oncology News Source Type: news
Bristol-Myers immunotherapy combo outperforms chemo in lung cancer survival: study
About 40% of patients who received a combination of Bristol-Myers Squibb Co's immuno-oncology drugs Opdivo and Yervoy as an initial treatment for advanced non-small cell lung cancer (NSCLC) were alive after two years, according to data presented at a medical meeting on Saturday. (Source: Reuters: Health)
Source: Reuters: Health - September 28, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
The Kidney Cancer Association Announces Recipients for the Advanced Discovery Awards (ADA) and Young Investigator Awards (YIA)
A total of $1.3 million awarded to advance new treatments for kidney cancerHOUSTON– September 16, 2019– The Kidney Cancer Association (KCA) is pleased to announce the recipients of the Advanced Discovery Awards (ADA) and Young Investigator Awards (YIA). In April, the KCA approved $1.3 million in new grant funding to advance early detection and new treatments for kidney cancer. “The KCA was delighted by the high caliber of proposals received for both awards and are hopeful that this research will advance the medical community’s understanding of kidney cancer,” said Dr. Christopher Wood, Ch...
Source: Kidney Cancer Association - September 16, 2019 Category: Urology & Nephrology Source Type: news
Evaluating the Safety of Immunotherapy in NSCLC Patients With Comorbidities
Combination immunotherapy with nivolumab plus ipilimumab was examined as a first-line therapy for patients with advanced non–small-cell lung cancer. Results were presented at the International Associate for the Study of Lung Cancer 2019 World Conference on Lung Cancer. (Source: CancerNetwork)
Source: CancerNetwork - September 10, 2019 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news
CheckMate 204 Update: Practice-Changing for Brain Metastases? CheckMate 204 Update: Practice-Changing for Brain Metastases?
New data show that ipilimumab plus nivolumab can produce a long-term response in patients with melanoma and brain metastases, says Dr Jeffrey Weber.Medscape Oncology (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - September 9, 2019 Category: Radiology Tags: Hematology-Oncology Commentary Source Type: news
Nivolumab Plus Ipilimumab Beats Sunitinib for Advanced Kidney Cancer Nivolumab Plus Ipilimumab Beats Sunitinib for Advanced Kidney Cancer
Nivolumab plus ipilimumab is more effective than sunitinib as first-line treatment for patients with advanced renal-cell carcinoma (RCC), according to an extended follow-up of the ongoing CheckMate 214 trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 3, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
Creating a Patient Trial Community
When TJ Sharpe was diagnosed with Stage 4 melanoma in August 2012, his future looked bleak. He was 37 years old with two young children, the median lifespan for patients with his diagnosis was 18 months and treatment options were limited.Thanks to some knowledge of the pharmaceutical industry he soon realised his best chance of survival was to find a clinical trial. It was a daunting prospect, but his resolve was solid and, after undergoing six surgical operations and four immunotherapy treatments across two different clinical trials, he lived to tell the tale.“I was lucky,” says Sharpe, “I was aware of clinical tria...
Source: EyeForPharma - August 13, 2019 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news
Creating a Patient Trial Community
When TJ Sharpe was diagnosed with Stage 4 melanoma in August 2012, his future looked bleak. He was 37 years old with two young children, the median lifespan for patients with his diagnosis was 18 months and treatment options were limited.Thanks to some knowledge of the pharmaceutical industry he soon realised his best chance of survival was to find a clinical trial. It was a daunting prospect, but his resolve was solid and, after undergoing six surgical operations and four immunotherapy treatments across two different clinical trials, he lived to tell the tale.“I was lucky,” says Sharpe, “I was aware of clinical tria...
Source: EyeForPharma - August 13, 2019 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news
